[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Olivia Newton-John Cancer Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100649806","phase-1-olig2-inhibitor-ct-179-for-recurrent-and-newly-diagnosed-glioblastoma-100649806",false,"NCT07739017","OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma","A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma","OPAL","Inclusion Criteria:\n\n* Male or female aged ≥ 18 years at the time of signing informed consent\n* Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System\n* KPS score ≥ 70\n* Adequate organ function\n* Contraception during study participation, as applicable\n* Able to swallow tablets\n\nExclusion Criteria:\n\n* Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA)\n* Placement of Gliadel wafers or similar local therapy at time of surgery\n* Receive bevacizumab\n* Evidence of intracranial or intra-tumoral hemorrhage\n* Significant concomitant disorder or serious intercurrent illness\n* History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years\n* Treatment for HIV, hepatitis B, or hepatitis C\n* Any gastrointestinal disorder that could result in reduced absorption of CT-179\n* Any psychiatric illness or social situation that would limit compliance with study requirements\n* Dose of dexamethasone higher than 4 mg\u002Fday within 1 week of the first dose of study medication","ALL","18 Years","75 Years",{"count":21,"type":22},54,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.",[28,29],"Recurrent Glioblastoma","Newly Diagnosed MGMT Unmethylated Glioblastoma",[31,32,33],"Glioblastoma","Brain Tumour","OLIG2","NOT_YET_RECRUITING","2026-07-27",{"date":37,"type":38},"2026-07-31","ACTUAL",{"date":40,"type":22},"2026-12",{"date":42,"type":22},"2028-09",{"name":44,"class":45},"Olivia Newton-John Cancer Research Institute","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100647519","early-phase-1-pilot-radioembolisation-clinical-trial-assessing-safety-and-efficacy-in-recurrent-glioma-100647519","NCT07712770","Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma","Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma (PRECISE)","PRECISE","Inclusion Criteria:\n\n1. Age ≥18 years at the time of screening\n2. Histomolecular diagnosis of IDH-wildtype glioblastoma (as per WHO 2021)\n3. Prior treatment with radiotherapy and an alkylating agent\n4. Presence of measurable disease on brain MRI, as defined by RANO 2.0 criteria\n5. Radiologically confirmed disease progression as per RANO 2.0 criteria\n6. Lesion confined to a single focus, with a maximum diameter ≤6 cm, and located in a vascular territory amenable to selective intra-arterial catheterisation as assessed on baseline imaging and confirmed by planning angiography, cone beam CT, and \\[99mTc\\]Tc-MAA SPECT\u002FCT (where available)\n7. Stable neurological status; patients with epilepsy may be included if seizures are controlled on a stable dose of anti-epileptic medication\n8. ECOG performance status 0-2\n9. Estimated life expectancy of ≥3 months, in the opinion of the investigator\n10. Adequate haematologic, renal, hepatic, and coagulation function at screening, defined as:\n\n    * Haemoglobin ≥9 g\u002FdL\n    * Absolute neutrophil count ≥1.5 x 109\u002FL\n    * Platelet count ≥100 x 109\u002FL\n    * Serum creatinine ≤1.5 x ULN, or creatinine clearance ≥30 mL\u002Fmin (Cockcroft-Gault formula)\n    * Total bilirubin ≤1.5 x ULN (except patients with known Gilbert's syndrome)\n    * Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤2.5 x ULN\n    * International normalized ratio (INR) ≤1.5 x ULN\n    * Prothrombin time (PT) or activated partial thromboplastin time (aPTT) ≤1.5 x ULN\n11. Ability to understand and comply with study requirements and provide written informed consent.\n\nExclusion Criteria:\n\n1. Multifocal glioma recurrence\n2. Tumour located in the posterior fossa or involving\u002Frisking critical subcortical structures (e.g. thalamus, hypothalamus, basal ganglia, internal capsule, cerebral peduncle, midbrain, brainstem, or optic pathways)\n3. Prior treatment with VEGF inhibitors\n4. Prior re-irradiation for progressive or recurrent disease\n5. Any local (surgery or radiotherapy) or systemic anti-cancer therapy within 28 days prior to the planned dose of the investigational treatment\n6. Concurrent use of any anti-cancer therapies, investigational drugs, or biological agents not specified in the protocol\n7. Contraindications to MRI, including but not limited to non-compatible implantable devices or severe claustrophobia\n8. Contraindications to catheter-based angiography, including but not limited to known bleeding disorders, significant vascular abnormalities precluding safe access, and severe allergy to contrast agents\n9. Pregnancy or breastfeeding. Women of childbearing potential and men with partners of childbearing potential must agree to use effective contraception during the study and for at least 4 months after the last procedure.\n10. Any severe or uncontrolled medical condition that, in the investigator's judgement, would pose an unacceptable risk to the patient or interfere with protocol compliance\n11. Cognitive or psychiatric conditions that would limit the ability to provide informed consent or adhere to study procedures\n12. Known hypersensitivity or allergy to 90Y-resin microspheres or any component of the investigational product",{"count":56,"type":22},12,[58],"EARLY_PHASE1","This study is testing a new way of treating brain tumours using tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres). These microspheres are placed into the blood vessels that feed the tumour. The treatment gives off radiation inside the tumour to try to stop it from growing.\n\nThis type of treatment is called Selective Internal Radiation Therapy (SIRT), Transarterial Radioembolisation (TARE), or radioembolisation. It is already an accepted treatment for patients with liver cancer. In this study, we are testing if this treatment can be done safely in the brain and how well it works.",[61,28],"Recurrent Glioblastoma IDH Wildtype",[63,64,65,66,67,68,69],"glioblastoma","SIR-spheres","Selective Internal Radiation Therapy","SIRT","Transarterial Radioembolisation","TARE","radioembolisation","2026-07-14",{"date":72,"type":38},"2026-07-17",{"date":74,"type":22},"2026-10",{"date":76,"type":22},"2028-11",{"name":44,"class":45},1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100642950","phase-2-radiotherapy-in-combination-with-glofitamab-in-relapsedrefractory-diffuse-large-b-cell-lymphoma-100642950","NCT07634289","Radiotherapy in Combination With Glofitamab in Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma","Radiotherapy in Combination With Glofitamab in Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma: The Phase II Radio-GLO Study","Radio-GLO","Inclusion Criteria:\n\n1. Age 18 years.\n2. Histologically proven relapsed\u002Frefractory CD20+ve DLBCL or a recognised subtype, including follicular large B-cell lymphoma and high grade B-cell lymphoma.\n3. Prior systemic treatment: ≥2 lines OR after 1 line AND autologous stem cell transplant\u002FCAR-T ineligible\n4. Eastern Collaborative Oncology Group (ECOG) performance status 0 to 2.\n5. Measurable FDG avid disease on baseline PET\u002FCT scan\n6. At least one site of active, PET positive disease that can be safely irradiated. Patients with disease only in previously irradiated sites that cannot be safely irradiated again due to tissue tolerance will be excluded.\n7. Adequate bone marrow function including:\n\n   * Haemoglobin \\>8.0 g\u002FdL\n   * White cell count (WCC) ≥2000\u002FμL\n   * Neutrophils \\>1.0 x 109\u002FL\n   * Platelets \\>75 x 109\u002FL at the time of study entry, unless attributed to lymphoma. Red cell transfusion is permitted.\n8. Adequate renal function with serum creatinine ≤1.5 x ULN or creatinine clearance (CrCl) ≥ 45mL\u002Fmin (using Cockcroft-Gault formula, Modification of Diet in Renal Disease Study Equation, 24hr urine collection, eGFR or a formal nuclear medicine technique) unless attributed to lymphoma (e.g. ureteric obstruction).\n9. Adequate hepatic function with AST\u002FALT ≤3x ULN and total bilirubin ≤1.5 x ULN (except subjects with Gilbert syndrome, who can have a total bilirubin ≤3 mg\u002FdL or ≤51.3 μmol\u002FL) unless attributed to lymphoma (e.g. liver infiltration or biliary obstruction).\n10. Adequate left ventricular ejection fraction of \\>40% as demonstrated on a Gated Cardiac Blood Pool Scan or echocardiogram.\n11. Life expectancy \\> 3 months.\n12. Patients of childbearing potential willing to adhere to the following contraceptive precautions:\n\n    For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as defined below:\n\n    Women must remain abstinent or use contraceptive methods with a failure rate of \\\u003C1% per year during the treatment period and for at least 6 months after the final dose of obinutuzumab and 2 months after the final dose of glofitamab. Women must refrain from donating eggs during this same period.\n\n    A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and\u002For uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.\n\n    Examples of contraceptive methods with a failure rate of \\\u003C1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n\n    The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized acceptable methods of contraception and information about the reliability of abstinence will be described in the local Informed Consent Form.\n\n    For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:\n\n    With a female partner of childbearing potential or pregnant female partners, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C1% per year during the treatment period and for at least 6 months after obinutuzumab, and 2 months after the final dose of glofitamab or tocilizumab to avoid exposing the embryo. Men must refrain from donating sperm during this same period.\n\n    The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n13. Written, informed consent.\n\nExclusion Criteria:\n\n1. Patient has failed only one prior line of therapy and is a candidate for stem cell\n2. Transplantation or CAR-T cell therapy\n3. Excessively bulky or rapidly progressive disease that, in the opinion of the investigator, requires rapid debulking or is unsafe to be irradiated\n4. Richter's transformation from CLL. Transformation from other low-grade histology (e.g. Follicular lymphoma, Marginal zone lymphoma etc) is permitted\n5. Refractory to prior therapy with glofitamab or other anti-CD3\u002FCD20 bispecific antibodies, defined as progression during or within 3 months of cessation.\n6. Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 4 weeks or 5 half-lives (whichever is shorter) prior to first study treatment.\n7. Current central nervous system, meningeal involvement or spinal cord compression by lymphoma. Previous involvement is permitted if there is currently no active CNS disease.\n8. Patients with active, known or suspected autoimmune disease. Patients with well controlled type I diabetes mellitus, coeliac disease, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, vitiligo or psoriasis not requiring systemic treatment, or other conditions not expected to recur in the absence of an external trigger are permitted to enrol.\n9. Subjects with a condition requiring systemic treatment with either corticosteroids (\\>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration without prior discussion with the medical monitor. Inhaled or topical steroids, and adrenal replacement therapy are permitted in the absence of active autoimmune disease.\n10. Prior solid organ transplantation or allogeneic bone marrow transplantation within 6 months.\n11. Prior malignancy active within the previous 2 years except for those treated with curative intent and with a \\\u003C20% chance of relapse. Low-grade prostate cancer under observation or well controlled on hormone therapy is permitted. Resected or locally treated non-melanoma skin cancer is permitted.\n12. Uncontrolled or severe cardiovascular disease (NYHA class III or IV heart failure; myocardial infarction within the last 6 months of study entry); unstable angina; unstable cardiac arrhythmias; clinically significant pericardial disease.\n13. Any other serious active disease or infection that in the opinion of the investigator takes precedence over the DLBCL, or will impact on the ability to deliver study treatment.\n14. Any positive test result for hepatitis B or hepatitis C virus during screening indicating acute or chronic infection. Latent hepatitis B with undetectable viral load by PCR is allowable provided appropriate anti-viral prophylaxis is given as per institutional guidelines.\n15. Any positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) unless the viral load is fully suppressed for \\>2 years with a CD4 count of \\>350x106\u002FL and compliant with antiretroviral therapy.\n16. Any history of severe hypersensitivity reactions to other monoclonal antibodies.\n17. A history of allergy or intolerance (unacceptable AEs) to study drug components.\n18. Patients incarcerated or without Medicare\n19. Medical or psychiatric conditions that compromise the patient's ability to give informed consent.",{"count":88,"type":22},40,[90],"PHASE2","The goal of this clinical trial is to see if a new combination of standard of care radiotherapy treatment prior to administering the study drugs obinutuzumab and glofitamab in relapsed\u002Frefractory Diffuse Large B Cell Lymphoma patients is effective. The main question it aims to answer is:\n\nIf you are able to tolerate the study treatments, and whether your cancer responds to the study treatment, compared with other reported studies of standard care treatments.\n\nParticipants will have three parts they need to complete over a 5 year period.\n\n* Screening period over a 28 day period\n* Treatment period - Radiotherapy followed by 12 treatment cycles every three weeks (total time approx. 37 weeks)\n* Follow up, up to 4 years. Additional PET imaging studies will be performed in a cohort of patients (up to 6) who are willing to undergo infusions of 89Zr-Df-Crefmirlimab and 18F-Granzyme B for evaluation of the impact of radiotherapy plus glofitamab with relapsed diffuse large B-cell lymphoma.",[93],"Relapsed \u002FRefractory DLBCL",[95,96,97,85,98,99,100],"relapsed\u002Frefractory Diffuse Large B Cell lymphoma","Raditherapy","glofitamab","DLBCL","Obinutuzumab - Gazyva, Gazyvaro","Columvi","2026-06-03",{"date":103,"type":38},"2026-06-08",{"date":40,"type":22},{"date":106,"type":22},"2032-12",{"name":44,"class":45},5,""]